Cardiovascular Risk in Rheumatoid Arthritis – Early Detection and Management

Abstract

The study by Ud Din and Rahim offers an insightful evaluation of cardiovascular risk among patients with rheumatoid arthritis (RA), a population increasingly recognized for elevated cardiovascular morbidity and mortality. By employing the SCORE2 risk model in a cohort of 380 patients, the authors underscore the pivotal intersection of systemic inflammation, lipid abnormalities, and cardiovascular risk in RA—a connection that has profound clinical implications [1]. The retrospective design allowed the authors to leverage existing hospital records at DHQ Karak, ensuring a robust sample for analysis. Stratification of cardiovascular risk revealed that over a quarter of patients (25.8%) were high-risk, with nearly two-thirds falling into moderate-to-high risk categories. These findings reflect the substantial cardiovascular burden in RA patients, mirroring prior literature indicating that conventional cardiovascular risk models often underestimate true risk in this population [2,3]. Importantly, the study demonstrates a strong correlation between RA disease activity, measured via DAS28 scores, and cardiovascular risk. Patients with higher DAS28 scores exhibited elevated LDL, reduced HDL, and higher CRP levels, confirming the hypothesis that systemic inflammation drives dyslipidemia and accelerates atherogenesis in RA [4,5]. This reinforces the necessity of integrating cardiovascular risk assessment into routine RA management, particularly in high-activity patients. The authors also highlight the limitations of gender-based differences in cardiovascular risk, noting a nonsignificant association between sex and risk. While these findings warrant further investigation, they emphasize that traditional risk factors alone may not fully account for cardiovascular vulnerability in RA, and underscore the value of RA-specific risk assessment tools. The study’s methodology, including thorough data abstraction, DAS28 scoring, and application of the SCORE2 model, is rigorous and transparent. Although retrospective and single-center, the analysis provides a clinically relevant snapshot of RA-associated cardiovascular risk in a Pakistani population, filling an important gap in regional data. The authors appropriately recognize limitations, particularly the lack of data on treatment regimens and their impact on cardiovascular outcomes—a variable that may modulate inflammation and lipid profiles. From a therapeutic standpoint, the study reinforces the dual benefits of controlling RA disease activity through disease-modifying antirheumatic drugs (DMARDs) and biologics. TNF inhibitors, IL-6 blockers, and rituximab not only mitigate joint inflammation but may also reduce systemic inflammatory burden, potentially attenuating cardiovascular risk [6,7]. Moreover, early lipid management, including statin therapy in high-risk patients, is advocated to further reduce long-term cardiovascular complications. In the context of low- and middle-income countries such as Pakistan, the study underscores the importance of resource-conscious strategies for early cardiovascular risk detection. Practical tools like SCORE2, combined with routine lipid profiling and inflammatory marker assessment, offer an accessible means to identify high-risk patients. Future research should build on this foundation, employing prospective designs, advanced imaging modalities, and multicenter cohorts to refine risk stratification and guide timely interventions [8,9]. In conclusion, Ud Din and Rahim effectively highlight the intertwined pathophysiology of RA and cardiovascular disease, demonstrating that disease activity is a critical determinant of cardiovascular risk. Their work advocates for early screening, proactive management, and interdisciplinary collaboration between rheumatologists and cardiologists. Integrating RA-specific cardiovascular risk assessment into standard clinical practice is likely to improve patient outcomes and reduce the long-term burden of cardiovascular complications in this vulnerable population. AUTHORS' CONTRIBUTION IU: Concept and design, data acquisition, interpretation, drafting, final approval, and agree to be accountable for all aspects of the work. Acknowledgment: None. Funding: No specific grant for this research from any public, commercial, or not-for-profit funding agency References Ud Din I, Rahim A. Cardiovascular Risk in Rheumatoid Arthritis: Early Detection and Management. Pak Heart J. 2025;58(04):472-478. DOI: 10.47144/phj.v58i4.3023 Popescu D, Rezus E, Badescu MC, Dima N, Seritean Isac PN, Dragoi IT, et al. Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy. Life (Basel). 2023;13(2):319. DOI: 10.3390/life13020319 Ferraz-Amaro I, Corrales A, Atienza-Mateo B, Vegas-Revenga N, Prieto-Peña D, Sánchez-Martín J, et al. SCORE2 Assessment in the Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis. Diagnostics (Basel). 2021;11(12):2363. DOI: 10.3390/diagnostics11122363 Anyfanti P, Ainatzoglou A, Angeloudi E, Michailou O, Defteraiou K, Bekiari E, et al. Cardiovascular Risk in Rheumatoid Arthritis: Considerations on Assessment and Management. Mediterr J Rheumatol. 2024;35(3):402-410. DOI: 10.31138/mjr.310824.cri Atzeni F, Maiani S, Corda M, Rodríguez-Carrio J. Diagnosis and management of cardiovascular risk in rheumatoid arthritis: main challenges and research agenda. Expert Rev Clin Immunol. 2023;19(3):279-292. DOI: 10.1080/1744666X.2023.2170351 Ahmed O, Krishnamurthy V, Kaba RA, Tahir H. The management of cardiovascular disease risk in patients with rheumatoid arthritis. Expert Opin Pharmacother. 2022;23(8):947-958. DOI: 10.1080/14656566.2022.2076594 Halacoglu J, Shea LA. Cardiovascular Risk Assessment and Therapeutic Implications in Rheumatoid Arthritis. J Cardiovasc Transl Res. 2020;13(5):878-890. DOI: 10.1007/s12265-020-09964-9 Hannawi SM, Hannawi H, Al Salmi I. Cardiovascular Risk in Rheumatoid Arthritis: Literature Review. Oman Med J. 2021;36(3):e262. doi: 10.5001/omj.2021.25 Ikdahl E, Stensrud MJ. Re-evaluating the mythical divide between traditional and novel cardiovascular risk factors in rheumatoid arthritis. RMD Open. 2024;10(1):e003954. DOI: 10.1136/rmdopen-2023-003954